Latest Raloxifene Stories
ROCKVILLE, Md., Sept.
Drugs used to lower the risk of breast cancer in women have the side effect of increasing the likelihood of blood clots, researchers in Oregon say. The study, published in the current issue of Annals of Internal Medicine, examined the effects of tamoxifen, raloxifene and tibolone reduce the risk of invasive breast cancer by 30 percent to 68 percent.
DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis.
The Indiana pharmaceutical firm Eli Lilly has announced a potential treatment for osteoporosis had disappointing results in a five-year clinical trial. Lilly officials said Tuesday it will not apply to federal regulators for approval of arzoxifene, the Indianapolis Star reported. The announcement is a setback for Lilly.
Lilly Continues to Defend Intellectual Property Rights for Evista INDIANAPOLIS, April 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S.
WASHINGTON, April 20 /PRNewswire-USNewswire/ -- Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center announce the recruitment of one of the world's most respected cancer researchers, V. Craig Jordan, OBE, PhD, DSc,.
INDIANAPOLIS, April 3 /PRNewswire-FirstCall/ --The Court of Appeals for the Federal Circuit in Washington, D.C. today overturned a lower court decision and ruled in favor of Eli Lilly and Company (NYSE: LLY) in the case of Ariad Pharmaceuticals et al. v. Eli Lilly and Company.
Lilly Vows to Defend Intellectual Property Rights INDIANAPOLIS, March 9 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals.
A large study of tibolone, a synthetic steroid used to treat menopausal symptoms and to prevent osteoporosis, was stopped six months early after researchers found that the drug substantially increased the risk of a relapse in breast cancer patients.
- Emitting flashes of light; glittering.